94 related articles for article (PubMed ID: 11070935)
1. [Prevention of hepatitis B flare-up using lamivudine in a patient with non-Hodgkin's lymphoma after allogeneic bone marrow transplantation].
Sunami K; Fujiwara T; Yoshida C; Fujii S; Fukuda S; Sezaki T
Rinsho Ketsueki; 2000 Sep; 41(9):733-8. PubMed ID: 11070935
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation.
Picardi M; Selleri C; De Rosa G; Raiola A; Pezzullo L; Rotoli B
Bone Marrow Transplant; 1998 Jun; 21(12):1267-9. PubMed ID: 9674862
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation.
Hashino S; Nozawa A; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Hige S; Asaka M
Bone Marrow Transplant; 2002 Feb; 29(4):361-3. PubMed ID: 11896435
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.
Stroffolini T; Andriani A; Bibas M; Barlattani A
Ann Hematol; 2002 Jan; 81(1):48-9. PubMed ID: 11807636
[TBL] [Abstract][Full Text] [Related]
6. Successful allogeneic bone marrow transplantation from an HBV-positive donor into an HBV-positive recipient using lamivudine.
Hashino S; Takahata M; Nozawa A; Izumiyama K; Chiba K; Suzuki S; Hige S; Asaka M
Bone Marrow Transplant; 2002 Feb; 29(3):269-71. PubMed ID: 11859401
[TBL] [Abstract][Full Text] [Related]
7. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
Nakagawa M; Simizu Y; Suemura M; Sato B
Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
[TBL] [Abstract][Full Text] [Related]
8. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
9. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
Shitrit AB; Kramer MR; Bakal I; Morali G; Ben Ari Z; Shitrit D
Ann Thorac Surg; 2006 May; 81(5):1851-2. PubMed ID: 16631684
[TBL] [Abstract][Full Text] [Related]
13. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
Ben-Ari Z; Broida E; Kittai Y; Chagnac A; Tur-Kaspa R
Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
[TBL] [Abstract][Full Text] [Related]
15. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
[TBL] [Abstract][Full Text] [Related]
16. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
Seehofer D; Rayes N; Steinmüller T; Müller AR; Settmacher U; Neuhaus R; Radke C; Berg T; Hopf U; Neuhaus P
Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
[TBL] [Abstract][Full Text] [Related]
17. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
18. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region.
Kitano K; Kobayashi H; Hanamura M; Furuta K; Ueno M; Rokuhara A; Tanaka E; Umemura T; Kiyosawa K
Eur J Haematol; 2006 Sep; 77(3):255-8. PubMed ID: 16923112
[TBL] [Abstract][Full Text] [Related]
19. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
Lau GK; He ML; Fong DY; Bartholomeusz A; Au WY; Lie AK; Locarnini S; Liang R
Hepatology; 2002 Sep; 36(3):702-9. PubMed ID: 12198664
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
